Alume Biosciences: Funding, Investors & Team (Oct 2026)
Alume is a biotechnology company, developing nerve-targeted pharmaceutical agents for surgical and therapeutic use. The company's first product, ALM-488, is a fluorescently labeled peptide-dye conjugate that makes human nerves "glow," helping surgeons reduce injury to critical nerves during surgery. During surgery, inadvertent injury to nerves leads to loss of function, including paralysis, numbness, and decreased quality of life. Alume intends to develop agents including ALM-488 to be used as an adjunct during surgery to help surgeons see nerves better compared to current visualization with white light alone. Alume's technology has the potential to improve the accuracy of nerve identification, decrease operative time, and lead to better outcomes for patients.
Alume Biosciences has raised $21.9M across 3 funding rounds on record, the most recent a Series B of $13.0M announced in Jan 2023.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alume Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2023.
Alume Biosciences Funding Rounds
Alume Biosciences raised $5.5M in an undisclosed round announced in May 2020.
2.3 years later, a Grant of $3.4M was announced in Sep 2022.
4 months later, a Series B of $13.0M was announced in Jan 2023.
Alume Biosciences Founders and Leadership Team
Contact details for the Alume Biosciences team: 1 of 1 has an email address on file.
Start 14-day free trial →Alume Biosciences Funding Compared to Other Biotechnology Startups
Alume Biosciences' latest round of $13.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alume Biosciences in Biotechnology and San Diego
Companies Similar to Alume Biosciences
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Alume Biosciences Funding FAQs
What does Alume Biosciences do?
Alume is a biotechnology company, developing nerve-targeted pharmaceutical agents for surgical and therapeutic use. The company's first product, ALM-488, is a fluorescently labeled peptide-dye conjugate that makes human nerves "glow," helping surgeons reduce injury to critical nerves during surgery. During surgery, inadvertent injury to nerves leads to loss of function, including paralysis, numbness, and decreased quality of life. Alume intends to develop agents including ALM-488 to be used as an adjunct during surgery to help surgeons see nerves better compared to current visualization with white light alone. Alume's technology has the potential to improve the accuracy of nerve identification, decrease operative time, and lead to better outcomes for patients.
How much funding has Alume Biosciences raised?
Alume Biosciences has raised $21.9M across 3 rounds on record. The most recent is a Series B of $13.0M announced in Jan 2023.
When did Alume Biosciences last raise funding?
Alume Biosciences' most recent funding round on record is a Series B of $13.0M, announced in Jan 2023.
Who is the CEO of Alume Biosciences?
Quyen Nguyen is listed as CEO at Alume Biosciences.
Where is Alume Biosciences headquartered?
Alume Biosciences is based in San Diego, California, United States.
How many employees does Alume Biosciences have?
Alume Biosciences is in the 11-50 employee band.
How does Alume Biosciences' funding compare to other Biotechnology startups?
Alume Biosciences' latest round of $13.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Alume Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alume Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.